Thies, Svenja; Langer, Rupert (2013). Tumor Regression Grading of Gastrointestinal Carcinomas after Neoadjuvant Treatment. Frontiers in oncology, 3, p. 262. Frontiers Research Foundation 10.3389/fonc.2013.00262
|
Text (PDF)
fonc-03-00262.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview |
Multimodal therapy concepts have been successfully implemented in the treatment of locally advanced gastrointestinal malignancies. The effects of neoadjuvant chemo- or radiochemotherapy such as scarry fibrosis or resorptive changes and inflammation can be determined by histopathological investigation of the subsequent resection specimen. Tumor regression grading (TRG) systems which aim to categorize the amount of regressive changes after cytotoxic treatment mostly refer onto the amount of therapy induced fibrosis in relation to residual tumor or the estimated percentage of residual tumor in relation to the previous tumor site. Commonly used TRGs for upper gastrointestinal carcinomas are the Mandard grading and the Becker grading system, e.g., and for rectal cancer the Dworak or the Rödel grading system, or other systems which follow similar definitions. Namely for gastro-esophageal carcinomas these TRGs provide important prognostic information since complete or subtotal tumor regression has shown to be associated with better patient's outcome. The prognostic value of TRG may even exceed those of currently used staging systems (e.g., TNM staging) for tumors treated by neoadjuvant therapy. There have been some limitations described regarding interobserver variability especially in borderline cases, which may be improved by standardization of work up of resection specimen and better training of histopathologic determination of regressive changes. It is highly recommended that TRG should be implemented in every histopathological report of neoadjuvant treated gastrointestinal carcinomas. The aim of this review is to disclose the relevance of histomorphological TRG to accomplish an optimal therapy for patients with gastrointestinal carcinomas.
Item Type: |
Journal Article (Review Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Service Sector > Institute of Pathology 04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology |
UniBE Contributor: |
Thies, Svenja, Langer, Rupert |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
2234-943X |
Publisher: |
Frontiers Research Foundation |
Language: |
English |
Submitter: |
Andrea Arnold |
Date Deposited: |
07 Apr 2014 10:40 |
Last Modified: |
05 Dec 2022 14:31 |
Publisher DOI: |
10.3389/fonc.2013.00262 |
PubMed ID: |
24109590 |
Uncontrolled Keywords: |
tumor regression grade, histopathology, gastrointestinal cancer, neoadjuvant therapy |
BORIS DOI: |
10.7892/boris.45916 |
URI: |
https://boris.unibe.ch/id/eprint/45916 |